{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T20:47:45Z","timestamp":1785358065276,"version":"3.55.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2016,7,5]],"date-time":"2016-07-05T00:00:00Z","timestamp":1467676800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100010902","name":"Novartis Pharmaceuticals Corporation and Vanda Pharmaceuticals, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010902","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s40263-016-0345-4","type":"journal-article","created":{"date-parts":[[2016,7,5]],"date-time":"2016-07-05T05:55:57Z","timestamp":1467698157000},"page":"735-747","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["A Randomized Trial of Iloperidone for Prevention of Relapse in Schizophrenia: The REPRIEVE Study"],"prefix":"10.1007","volume":"30","author":[{"given":"Peter J.","family":"Weiden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Manning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curt D.","family":"Wolfgang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Michael","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Mancione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyang","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mallery G.","family":"Mayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,5]]},"reference":[{"key":"345_CR1","unstructured":"Fanapt (iloperidone) [prescribing information]. Washington, DC: Vanda Pharmaceuticals Inc.; 2014."},{"key":"345_CR2","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S0893-133X(01)00285-8","volume":"25","author":"HO Kalkman","year":"2001","unstructured":"Kalkman HO, Subramanian N, Hoyer D. Extended radioligand binding profile of iloperidone: a broad spectrum dopamine\/serotonin\/norepinephrine receptor antagonist for the management of psychotic disorders. Neuropsychopharmacology. 2001;25:904\u201314.","journal-title":"Neuropsychopharmacology."},{"key":"345_CR3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1017\/S1092852912000764","volume":"18","author":"AJ Cutler","year":"2013","unstructured":"Cutler AJ, Kalali AH, Mattingly GW, Kunovac J, Meng X. Long term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial. CNS Spectr. 2013;18:43\u201354.","journal-title":"CNS Spectr."},{"key":"345_CR4","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3371\/CSRP.6.1.5","volume":"6","author":"PJ Weiden","year":"2012","unstructured":"Weiden PJ. Iloperidone for the treatment of schizophrenia: an updated clinical review. Clin Schizophr Relat Psychoses. 2012;6:34\u201344.","journal-title":"Clin Schizophr Relat Psychoses."},{"issue":"2 Suppl 1","key":"345_CR5","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1097\/JCP.0b013e318169d4ce","volume":"28","author":"AJ Cutler","year":"2008","unstructured":"Cutler AJ, Kalali AH, Weiden PJ, Hamilton J, Wolfgang CD. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol. 2008;28(2 Suppl 1):S20\u20138.","journal-title":"J Clin Psychopharmacol."},{"issue":"2 Suppl 1","key":"345_CR6","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1097\/JCP.0b013e3181694f5a","volume":"28","author":"PJ Weiden","year":"2008","unstructured":"Weiden PJ, Cutler AJ, Polymeropoulos MH, Wolfgang CD. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials. J Clin Psychopharmacol. 2008;28(2 Suppl 1):S12\u20139.","journal-title":"J Clin Psychopharmacol."},{"issue":"2 Suppl 1","key":"345_CR7","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1097\/JCP.0b013e318169cca7","volume":"28","author":"JM Kane","year":"2008","unstructured":"Kane JM, Lauriello J, Laska E, Di Marino M, Wolfgang CD. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia. J Clin Psychopharmacol. 2008;28(2 Suppl 1):S29\u201335.","journal-title":"J Clin Psychopharmacol."},{"issue":"2 Suppl 1","key":"345_CR8","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1097\/JCP.0b013e3181692787","volume":"28","author":"SG Potkin","year":"2008","unstructured":"Potkin SG, Litman RE, Torres R, Wolfgang CD. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. J Clin Psychopharmacol. 2008;28(2 Suppl 1):S4\u201311.","journal-title":"J Clin Psychopharmacol."},{"key":"345_CR9","unstructured":"Baroldi P, Wolfgang CD, Fisher D. A pharmacokinetic (PK)-pharmacodynamic (PD) relationship exists for efficacy of iloperidone, a novel investigational atypical antipsychotic agent. Paper presented at: American Psychiatric Association Annual Meeting, May 19\u201324, 2007, San Diego, CA."},{"key":"345_CR10","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.schres.2013.11.042","volume":"153","author":"PJ Weiden","year":"2014","unstructured":"Weiden PJ, Citrome L, Alva G, Brams M, Glick ID, Jackson R, et al. A trial evaluating gradual- or immediate-switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia. Schizophr Res. 2014;153:160\u20138.","journal-title":"Schizophr Res."},{"key":"345_CR11","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3371\/CSRP.CIWE.103114","volume":"8","author":"L Citrome","year":"2015","unstructured":"Citrome L, Weiden PJ, Alva G, Glick ID, Jackson R, Mattingly G, et al. Switching to iloperidone: an omnibus of clinically relevant observations from a 12-week, open-label, randomized clinical trial in 500 persons with schizophrenia. Clin Schizophr Relat Psychoses. 2015;8:183\u201395.","journal-title":"Clin Schizophr Relat Psychoses."},{"key":"345_CR12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/JCP.0b013e31827c0314","volume":"33","author":"SG Potkin","year":"2013","unstructured":"Potkin SG, Preskorn S, Hochfeld M, Meng X. A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and\/or CYP3A4 and a comparison to quetiapine and ziprasidone. J Clin Psychopharmacol. 2013;33:3\u201310.","journal-title":"J Clin Psychopharmacol."},{"key":"345_CR13","first-page":"4","volume":"20","author":"JB Lohr","year":"2015","unstructured":"Lohr JB, Eidt CA, Alfaraj AA, Soliman MA. The clinical challenges of akathisia. CNS Spectr. 2015;20:4\u201314.","journal-title":"CNS Spectr."},{"key":"345_CR14","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/00004714-198308000-00006","volume":"3","author":"MK Shear","year":"1983","unstructured":"Shear MK, Frances A, Weiden P. Suicide associated with akathisia and depot fluphenazine treatment. J Clin Psychopharmacol. 1983;3:235\u20136.","journal-title":"J Clin Psychopharmacol."},{"key":"345_CR15","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/archpsyc.1990.01810200069010","volume":"47","author":"DF Levinson","year":"1990","unstructured":"Levinson DF, Simpson GM, Singh H, et al. Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment. Arch Gen Psychiatry. 1990;47:761\u20138.","journal-title":"Arch Gen Psychiatry."},{"key":"345_CR16","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1176\/ajp.141.1.16","volume":"141","author":"T Putten Van","year":"1984","unstructured":"Van Putten T, May PR, Marder SR. Response to antipsychotic medication: the doctor\u2019s and the consumer\u2019s view. Am J Psychiatry. 1984;141:16\u20139.","journal-title":"Am J Psychiatry."},{"key":"345_CR17","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1093\/oxfordjournals.schbul.a007027","volume":"29","author":"S Hirose","year":"2003","unstructured":"Hirose S. The causes of underdiagnosing akathisia. Schiz Bull. 2003;29:547\u201358.","journal-title":"Schiz Bull."},{"key":"345_CR18","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1176\/ajp.144.9.1148","volume":"144","author":"PJ Weiden","year":"1987","unstructured":"Weiden PJ, Mann JJ, Haas G, et al. Clinical nonrecognition of neuroleptic-induced movement disorders: a cautionary study. Am J Psychiatry. 1987;144:1148\u201353.","journal-title":"Am J Psychiatry."},{"key":"345_CR19","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1017\/S1092852913000850","volume":"18","author":"SM Stahl","year":"2013","unstructured":"Stahl SM. Role of \u03b11 adrenergic antagonism in the mechanism of action of iloperidone: reducing extrapyramidal symptoms. CNS Spectr. 2013;18:285\u20138.","journal-title":"CNS Spectr."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-016-0345-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-016-0345-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-016-0345-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T00:45:51Z","timestamp":1589676351000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-016-0345-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,5]]},"references-count":19,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["345"],"URL":"https:\/\/doi.org\/10.1007\/s40263-016-0345-4","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,5]]}}}